XPhyto Therapeutics Enters Exclusive Cannabis Research and Development Agreement with the Technical University of Munich

XPhyto Therapeutics 与慕尼黑技术大学签订独家大麻研究与开发协议

2019-08-15 00:26:12 CFN Media Group


Vancouver, British Columbia– – XPhyto Therapeutics Corp. is pleased to announce that its wholly owned German subsidiary, Bunker Pflanzenextrakte GmbH , has entered into an exclusive cannabis research and development agreement with the department of biochemistry at the Technical University of Munich . Pursuant to the R&D Agreement, initial research will focus on the identification and assessment of novel research and development approaches to utilize the cannabis plant and its derivatives, including cannabinoids, terpenes, terpenoids, polyphenols and flavones. Promising targets will be advanced through pilot studies and pending preliminary success, pursued via separate joint research projects on a case-by-case basis for potential commercialization. “XPhyto is honored to have the privilege of working with TUM. Their commitment to research excellence and their reputation for commercial development makes them a highly attractive partner,” said Robert Barth, VP European Corporate Development, XPhyto and Managing Director, Bunker. “TUM’s strong interest in cannabis research demonstrates a progressive attitude toward an emerging and highly relevant global industry.” TUM has a reputation as an entrepreneurial institution and is the only technical university in Germany to be recognized as one of the country’s “Universities of Excellence” every year since the program began in 2006. TUM has achieved success in all three lines of funding under the Excellence Initiative organized by the German government and the federal states: Institutional Strategy, Clusters of Excellence and Graduate Schools. About XPhyto Therapeutics Corp. XPhyto is a science-based cannabis company focused on formulation, clinical validation, and emerging European markets. XPhyto’s 100% owned German subsidiary, Bunker Pflanzenextrakte GmbH, has been granted a unique German cannabis cultivation and extraction licence for scientific purposes by the German Federal Institute for Drugs and Medical Devices (BfArM). XPhyto is pursuing additional opportunities in Germany including cultivation, processing, manufacturing, import, and distribution. In Canada, two exclusive 5-year engagements with the Faculty of Pharmacy at a major Canadian university provide certified extraction, isolation, and formulation facilities, drug research and development expertise, as well as commercial analytical testing capability. For further information, please contact: Hugh Rogers CEO & Director +1.780.818.6422 [email protected] www.xphyto.com Robert Barth VP European Corporate Development +49 8331 99481 10 [email protected] Forward looking statements This news release includes statements containing forward-looking information within the meaning of applicable Canadian securities law (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “develop”, “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “potential”, “propose” and other similar words, or statements that certain events or conditions “may” or “will” occur, and in this release include the statement regarding the Company’s goal of building an industry leading medical cannabis company Forward-looking statements are only predictions based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements, including: that the Company may not derive the expected, or any, benefits from the Licence; that the Company may be unable to scale its business; product liability risks; frequent changes to cannabis regulations in Canada and internationally; general economic conditions; adverse industry events; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; competition; international risks; and other risks beyond the Company’s control. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this news release.
加拿大不列颠哥伦比亚省温哥华—— XPhyto Therapeutics Corp .高兴地宣布,其全资德国子公司 Bunker Pfranzenkatekte GmbH 已与慕尼黑技术大学生物化学系签订了大麻研究和开发独家协议。 根据《研发协议》,初步研究将侧重于确定和评估利用大麻植物及其衍生物,包括大麻素、萜类、萜类、多酚和黄酮类的新研发方法。承诺的目标将通过试点研究和初步成功推进,通过单独的联合研究项目在个案基础上进行潜在的商业化。 “ XPhyto 有幸与 TUM 合作。他们对卓越研究的承诺以及他们在商业发展方面的声誉使他们成为一个极具吸引力的合作伙伴,” XPhyto 欧洲企业发展副总裁兼 Bunker 董事总经理 Robert Barth 说。“ TUM 对大麻研究的浓厚兴趣表明,它对一个新兴的、高度相关的全球产业采取了积极的态度。” TUM 作为一家创业机构享有声誉,是德国自2006年启动该项目以来每年唯一一所被公认为国家“优秀大学”之一的技术大学。TUM 在德国政府和联邦各州组织的卓越计划下获得了所有三个基金项目的成功:机构战略、卓越集群和研究生院。 关于 XPhyto Therapeutics Corp 。 XPhyto 是一家以科学为基础的大麻公司,专注于制剂、临床验证和欧洲新兴市场。XPhyto 拥有100%股权的德国子公司 Bunker Pfranzenkatekte GmbH 已获得德国联邦药物和医疗器械研究所( BfArM )颁发的用于科学目的的独特的德国大麻种植和提取许可证。XPhyto 正在德国寻求更多的机会,包括种植、加工、制造、进口和分销。在加拿大,与加拿大一所主要大学的药剂系进行了两次为期5年的独家合作,提供了经认证的提取、隔离和制剂设施、药物研发专业知识以及商业分析测试能力。 详情请联络: 休·罗杰斯 首席执行官兼董事 +1.780.818.6422 [受电邮保护] www.xplato.com 罗伯特·巴思 欧洲企业发展副总裁 +49833199481 [受电邮保护] 前瞻性陈述 本新闻稿包括包含适用加拿大证券法意义内的前瞻性信息的声明(“前瞻性声明”)。前瞻性陈述经常以“开发”、“计划”、“继续”、“预期”、“项目”、“意向”、“相信”、“预期”、“估计”、“潜力”、“提议”等类似词语或某些事件或条件“可能”或“将”发生的陈述为特征;本新闻稿中包括关于公司打造行业领先医用大麻公司的目标的声明前瞻性声明,仅是基于管理层在声明作出之日的意见和估计作出的预测,并受各种风险和不确定性以及可能导致实际事件或结果与前瞻性声明中预测的结果存在重大差异的其他因素的影响,包括:公司可能无法得出预期或任何许可证带来的好处;公司可能无法扩大业务规模;产品责任风险;加拿大和国际大麻法规的频繁变更;一般经济条件;不利的行业事件;未来的立法和监管发展;无法从内部和外部来源获得足够的资本,和/或无法以优惠条件获得足够的资本;竞争;国际风险;以及公司无法控制的其他风险。除适用法律明确要求外,本公司并无责任,并明确表示概括性声明不会因新信息、未来事件或其他原因而更新或修订。 CSE 或其市场监管机构(如 CSE 政策中定义的术语)均不对本新闻稿的充分性或准确性承担责任。